Feb. DTR Chart: Medicaid Top 20 states by enrollment

Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain medicine that might offer hope for those struggling with acute pain issues who want to avoid opioids and NSAIDs.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Check out this list of the top five articles posted on Formulary Watch this year!

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Gene therapies are revolutionizing treatment for hemophilia A and sickle cell disease; however, they are saddled with hefty price tags and limited patient populations that are impacting uptake.

Currently, the only medications approved by the FDA for PTSD are the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine. However, these medications don’t work for everyone.